Fortis Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-914
Closed -$232K 90
2021
Q4
$232K Buy
914
+284
+45% +$83K 0.12% 74
2021
Q3
$242K Sell
630
-377
-37% -$139K 0.13% 100
2021
Q2
$237K Buy
+1,007
New +$180K 0.12% 108

Other funds holding MRNA

Fortis Capital Management's MRNA Position: Q1 2022 in Review

Fortis Capital Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 914 shares — an estimated $232K sold.

Fortis Capital Management first reported a position in MRNA in Q2 2021 and held it in 3 quarters. The position peaked at $242K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Fortis Capital Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Fortis Capital Management sold 914 Moderna shares in Q1 2022, an estimated $232K.
  • Fortis Capital Management first reported a position in Moderna in Q2 2021 and held it in 3 quarters.
  • Fortis Capital Management's Moderna position peaked at $242K in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Fortis Capital Management's 13F filing for Q1 2022, filed 13 May 2022.